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Impedimetric affinity biosensors are, without any doubt, among
the most sensitive analytical devices available, offering low
limits of detection and wide linear response ranges. There are,
however, only a few papers detailing the application of
impedimetric biosensors for the analysis of clinically relevant
samples with due clinical performance. The fact that these
devices have not found their way to any commercial or clinical
use to date might be surprising, since an electrochemical assay
platform based on portable potentiostats is a success story for
monitoring a range of clinical parameters such as ions,
haematological indicators and glucose. This review discusses
the reasons behind this discrepancy and addresses the barriers
to be overcome in order to achieve the point-of-care diagnos-
tics using such devices for detection of protein oncomarkers
approved by FDA. The final part of the review covers the most
recent progress in the area.
1. Introduction
Portable electrochemical detection-based devices are common
and have long been available with applications in environ-
mental monitoring, the food industry[1–3] and also clinical
diagnostics (e.g., Piccolo Xpress or iStat handheld analyzers
for measuring different ions or haematological parameters,
such as haemoglobin, Hb).[4–6] Home glucose tests for monitor-
ing diabetes are the most widely used,[7–9] despite the existence
of similar devices for diabetics based on the MediSen-
seOptiumTM platform.[10] The vast majority of biosensors
(devices designed to detect or quantify a biomolecule)
described in the literature to date involve enzyme-based
biosensors (e.g., especially those based on glucose oxidase
enzyme),[11] whilst immunosensors (antibody-based biosensors)
are also fairly common.[12–15] These devices belong to a family of
affinity biosensors which are based on a strong interaction
between antibodies and analyte molecules from a clinical
sample (e.g., blood, serum, urine, saliva, etc.).[12–14] Point-of-care
diagnostics can benefit from this assay platform due to its
various advantages, such as low assay cost and sample volume
requirement, portability, moderate degree of multiplexing and,
in special cases, also a label-free mode of operation.[16–19] Even
though the U.S. biosensor market size was estimated to be 14.8
billion $ in 2015 (and is still growing, estimated to be 29 billion
$ in 2024), impedimetric biosensors, although among the most
sensitive, have not yet penetrated this market.[20,21]
Out of all the electroanalytical methods, electrochemical
impedance spectroscopy (EIS) is one of the most complex,
affording several advantages over the commonly used amper-
ometry/potentiometry (e.g., wide linear range, low limit of
detection (LOD) and label-free mode of operation).[22] To over-
come the drawbacks of traditional laboratory electrochemical
instrumentations, complementary metal oxide semiconductor
instrumentation circuits have been reported and recently
summarized.[23] Very often, EIS is combined with different
nanostructured interfaces in order to increase the amount of
biorecognition elements on the surface, and, hence, to enhance
the performance of the biosensor in terms of assay sensitivity
and extension of linear range. Functionalized carbon nano-
materials (or even modified screen-printed electrodes, SPE),
such as graphene or boron-doped diamond, are currently
commonly used and commercially available for the immobiliza-
tion of biomolecules.[24–26] There exists, however, the prereq-
uisite that the stability of the SPE reference electrode is crucial
for the robustness of disposable impedimetric biosensors. The
reference electrode should ideally be non-polarizable, e.g.,
must provide high-exchange current densities, and thus should
not cause any potential drifts during storage and operation.[27,28]
This review focuses on the main principles and applications
of EIS and on the challenges to be overcome in order to
commercialize impedimetric biosensors for clinical diagnos-
tics.[29] Herein, only those papers related to detection of protein
biomarkers approved by the FDA (US Food and Drug Admin-
istration) are discussed and the reader is advised to read the
excellent review papers in the event of interest in the electro-
chemical/impedimetric detection of genetic biomarkers like
DNA, mRNA and miRNA for diagnostic purposes.[30–32] A section
on different circuit models for fitting, experimental data
evaluation and interpretation is also included, since this is
frequently the main source of errors and misunderstandings in
impedimetric measurements. Other problems, such as non-
specific interactions of high-abundant interferents in biological
matrices and reproducible, high-throughput analyses in an
array format of analysis are also discussed.
2. Theoretical Background of Impedance
Spectroscopy
(Operational) impedance is generally defined in accordance
with Eq. (1):
Z^ sð Þ ¼ L½e tð Þ
L½I tð Þ ¼
E sð Þ
I sð Þ ð1Þ
where L denotes Laplace transform, E and I denote the
potential and current, respectively, and the parameter s (in
classical Laplace transform expression is real, s=s, though it
[a] Dr. T. Bertok, Dr. L. Lorencova, E. Chocholova, Dr. E. Jane,
Dr. A. Vikartovska, Dr. J. Tkac
Department of Glycobiotechnology
Institution of Chemistry
Slovak Academy of Sciences
Dubravska cesta 9, 845 38 Bratislava, Slovakia
E-mail: Tomas.Bertok@savba.sk
Jan.Tkac@savba.sk
[b] Dr. P. Kasak
Center for Advanced Materials
Qatar University
Doha 2713, Qatar
An invited contribution to a Special Collection dedicated to Bioelec-
trochemistry
990ChemElectroChem 2019, 6, 989–1003 www.chemelectrochem.org  2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Reviews
Wiley VCH Donnerstag, 14.02.2019
1904 / 120400 [S. 990/1003] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
might also be complex, s=s+ jw) is denoted as the frequency.
This is generally valid for any potential perturbation; however,
in electrochemical impedance spectroscopy, an AC signal
stimulus is usually applied, hence the following Fourier trans-
form [Eq. (2)] is applied for sinusoidal perturbation:
Z^ jwð Þ ¼ F E tð Þ½ 
F I tð Þ½  ¼
~E jwð Þ
~I jwð Þ ¼ ZREAL wð Þ þ jZIMAG wð Þ ð2Þ
where for the so-called AC impedance, the parameter s is an
imaginary one, i. e., s= jw (j=
p1), ZREAL and ZIMAG are the real
and imaginary parts of the impedance, respectively. Besides
impedance, admittance (inverse expression of impedance, Y) is
a frequently used term, and impedance and admittance
together are denoted as immittances.[33,34] Electrical circuits
contain three passive elements, namely resistors, capacitors and
inductors. For AC impedance, mainly resistors (R) and capacitors
(C) are considered. For linear electrical elements R and C, the
AC impedance of these elements is R and 1/jwC, respectively.
The impedance of the total circuit with different elements in
series/parallel connection is then written using Ohm’s and
Kirchoff’s laws. The linear part (at lower frequencies) is only of
any physical significance in Faradaic EIS and represents the
delay arising from diffusion of electroactive species to the
electrode.[35]
However, various possible mechanisms for impedance
change upon the binding target analyte should be discussed.
The plot of the imaginary vs. real part of Z [as in Eq. (2)], the so-
called Nyquist plot (Figure 1, more correctly an Argand
diagram), is subsequently evaluated and fitted using a model
circuit to obtain the characteristics of the system under study,
such as double-layer capacitance (the sum of a constant
capacitance of an unmodified electrode and a variable
capacitance originating from a surface modifier) or electrolyte/
charge transfer (i. e., the sum of an unmodified electrode and
an introduced modifier) resistance.[32] For rough surfaces, the
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electronic properties of the interface cannot be adequately
described with a capacitive element, hence a constant phase
element (CPE) is used instead. Solid electrodes are not ideally
polarizable (compared to liquid ones like mercury), so they
usually do not retain a purely capacitive electrochemical
double-layer. The lack of homogeneity during impedance
studies is modelled with CPE, represented by the Q symbol in
the Randles-Erschler equivalent circuit, e.g., R(Q[RW]). The
impedance of CPE is described in Eq. (3) as:
ZQ ¼ 1=Y0 jwð Þn ð3Þ
where n is an empirical constant. When n approaches 1, the
CPE acts as an ideal capacitor and, by contrast, when n=0, it
becomes a pure resistor.[36] For impedimetric biosensors,
Faradaic EIS is most commonly used, i. e., using an electro-
chemical mediator dissolved in a working electrolyte, such as a
ferri/ferrocyanide redox couple.
However, when Faradaic EIS using a ferri/ferrocyanide redox
couple is combined with Au electrodes, the Au surface is
seriously damaged over time by Au atoms, which are etched by
CN ions and the process could not be completely suppressed
even under optimal conditions.[37] Hence, even though self-
assembled monolayers (SAMs) on Au electrodes offer several
advantages, such as possibility to control the surface density
and orientation of biorecognition elements, suppression of the
non-specific interactions (an issue addressed below), the ability
to tune initial RCT during an experiment (by properly chosen
terminal SAM functionalities) compared to other types of
electrodes,[38,39] the repeated or long-term use of such an Au
modified electrode should be avoided when using a Faradaic
EIS detection scheme.
3. Circuit Modelling, Data Interpretation and
Validation
Biorecognition events on the biosensor surface are usually
manifested as a phase and an amplitude shift in the response
relative to the stimulus signal, and typically modelled using a
Randles circuit (proposed by John Edward Brough Randles).[23,40]
However, accurate data interpretation might be difficult when
non-ideal Nyquist plots are obtained during an experiment
(caused by non-homogenous surface modification, interface
defects, etc.), such as two and more semi-circular regions.
Typical forms of a Nyquist diagram for different circuits are
shown in Figure 2. However, more complex, less ideal forms of
the plots may occur during a measurement.
Especially for biological interactions, these facts must be
carefully evaluated and require proper interpretation, which
can be a substantial impediment in the development of any
“user-friendly” portable device operated by a non-specialist
(e.g., a patient). The main reason is that impedimetric assays do
not permit a simple “click-and-go” measurement method in
most cases. Another challenge for point-of-care impedimetric
devices is assay selectivity for clinical applications, since whole
blood or serum contains a significant amount of non-target
molecules, which can be more abundant than the biomarker of
interest. Even though the impedimetric biosensors often afford
low LOD (down to fM/aM level)[41–43] and a wide linear response
range,[44,45] in many cases analyte pre-separation as well as a
nanoscale controlled surface chemistry need to be applied in
order to achieve biomarker detection without using additional
labels.
Figure 1. Complex plane Nyquist and Bode diagrams as projections within a
3D diagram (left). Two parameters i. e., double layer capacitance and charge
transfer resistance (semicircle diameter, RCT) are extracted from the Nyquist
plot (right). The RCT value (shown in detail on the right) tends to increase
after a biorecognition event takes place, but other issues may significantly
affect the RCT, such as electrostatic attraction/repulsion between a charged
layer (proteins, DNA, etc.) and a charged mediator.
Figure 2. Typical Nyquist plots for various electrical circuits, moving from
those that are the most simple to the most common. Upper row (from left
to right): pure resistor (R, only real part of impedance); pure capacitor (C,
only imaginary part of impedance); R and C in series connection. Middle row
(from left to right): R and C in parallel connection; R and C in parallel
connection with an electrolyte resistance (RE) – where RCT denotes the charge
(or electron) transfer resistance of the interface; the same circuit with
additional capacitance in series. Lower row left: Randles-Ershler equivalent
circuit, most commonly used for fitting impedimetric biosensor data, where
W stands for Warburg element (diffusion parameter for low frequencies).
Lower row right: more complex system with two semicircular regions, i. e.,
two interfacial charge transfer resistances. Reprinted from,[53] Copyright 2014
with permission from Elsevier.
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For instance, the prostate specific antigen (PSA, a prostate
cancer biomarker) needs to be selectively detected at concen-
trations of several ngmL1. Currently, more than 4.0 ngmL1
PSA level in blood is deemed to be pathological and further
examinations (often a biopsy) are needed to exclude other non-
malignant processes, such as benign prostate hyperplasia, and
to confirm prostate cancer.[46,47] For example, the application of
a biosensor for PSA detection in human serum without any
additional separation steps would be useless if a biosensor
would non-specifically bind human serum albumin, which is
present at a concentration 6 orders of magnitude higher (up to
50 mgmL1) than PSA. Controlled sample delivery to the device
interface is also an important additional step, since manual
sample delivery without any (micro)fluidics may lead to
significant errors affecting the device performance and clinical
outcome of such assays.
Frequency Response Analyzers (FRA modules) are com-
monly a part of laboratory potentiostats/galvanostats and
might also be a part of some portable devices (i. e., for
PalmSens or Ivium Technologies).[48,49] They are not intended for
diagnostic purposes, however. For these kinds of devices, there
is often a problem with shielding, since three main conditions
must be met for every impedimetric measurement: linearity
(the AC amplitude needs to be small enough to keep the
response linear, but at the same time high enough to increase
the signal-to-noise ratio), stability (the system cannot change
during measurement i. e., data acquisition) and causality (the
AC response needs to correlate with the AC stimulus only, i. e.,
shielding is an important feature, for example, for the small
currents obtained during potentiostatic EIS).[50] These three
conditions might be difficult to achieve in home diagnostic
devices, which is another important issue that needs to be
overcome for the commercial success of the impedimetric
biosensor design. Even though potentiostatic impedance
measurements are often performed using a wide range of
different frequencies, it is possible to measure the impedance
in real time at a single frequency or to perform assays using
devices with integrated microfluidics.[35,51] Once the data are
acquired, appropriate interpretation is crucial. This is often
a difficult task, even for a skilled scientist, since more than one
single-circuit model can actually meet the requirement to
obtain a statistically significant fitting.[52] It is a general rule that
the papers dealing with impedimetric biosensors usually use
the Randles equivalent circuit to obtain the RCT value as an
output signal. However, there are some papers dealing with the
“two semicircles” problem, although the vast majority do not
describe the application of biosensors.
Ohno et al. suggested that, for an IgA biosensor device, the
organic layer-modified electrode surface was actually divided
into two parts: an interfacial part (expressed as a parallel
connection of RCT and CDL) and an inner part (expressed as
constant R and CPE). After binding of the IgA sample to the
anti-IgA layer, only RCT increased, and LOD of 0.01 ngmL
1 could
be achieved.[54]
Other examples of using circuit models other than the
Randles circuit R(C[RW]) for Nyquist plots with two visible
semicircular regions have also been described, e.g., immuno-
sensors for the detection of ciprofloxacin antibiotic (using
R(RC)(RC) circuit with LOD of 10 pgmL1)[55], biosensors using
R(RC)(C(RW)) circuit for assay of interleukin-6 (with LOD of
10 agmL1) or 1,10-phenanthroline-5,6-dione- and glucose
oxidase-modified graphite electrode[56,57] and even for the
analysis of whole HeLa cells (for cervical cancer diagnostics)
using R(C(R(RC))) circuit with LOD of 10 cellsmL1.[58]
For non-Faradaic EIS measurements, Cole-Cole complex
capacitance plots (CIMAG vs. CREAL) are sometimes constructed
from data obtained during an experiment using the following
equation [(Eq. (4)][59]:
C* ¼ CI þ jCII ¼ 1
jwZ
¼ Z
II
jw Zj j2 ð4Þ
Davis’s group published a series of papers on impedance-
derived capacitance spectroscopy and its diagnostic utility (for
detection of prostatic acid phosphatase down to 11 pM and C-
reactive protein down to 28 pM).[60,61]
EIS affords a major advantage over other electroanalytical
methods i. e., validation of experimentally obtained data using
a Kramers-Kronig (KK) test. The KK relations are mathematical
expressions connecting the experimentally obtained imaginary/
real part of the impedance (or a complex function, in general)
with its real/imaginary counterpart. The experimental data are
fitted using a circuit which always satisfies KK relations, so the
KK transform (in combination with other methods) acts as an
independent check against invalid experimental data.[35,50,62,63]
This approach should always be applied to EIS assays and was
used, for example, for the validation of disposable biosensor
assays using a single-frequency impedance detecting haptoglo-
bin (Hp)[64] or HSP70 (heat shock protein 70, a tumor biomarker)
by the same SFI method down to 12 fgmL1 [65].
Besides Nyquist (ZIMAG vs. ZREAL) and Bode (modulus [W] /
phase [8] vs. frequency [Hz]) plots, two other types of plots may
serve as a validation tool for each point during EIS measure-
ments in real time. The first one is a Lissajou plot (AC current vs.
AC potential), which exhibits a central symmetry with regard to
the origin of the plot, when the linearity condition is fulfilled.
The second one is a Resolution plot (AC current and AC
potential vs. time), which indicates whether the sensitivity of
the system is sufficient and the noise is kept to a minimal
value.[66]
There are several free and commercially available software
packages for data evaluation and fitting (such as LEVM and EIS
spectrum analyzer or ZView and ZSimpWin, respectively)[35], and
all the methods previously described are commonly integrated
within the software that comes with the commercial potentio-
stats/galvanostats, such as NOVA software (Metrohm) or
PSTrace (PalmSens). Each potentially commercialized impedi-
metric biosensor needs to come with software for such data
validation in order to provide a user-friendly interface since,
due to the complexity of EIS measurements, it is impossible to
make such devices as simple as current glucose biosensors,
which essentially are a “black box“ for the user, not needing any
strategic intervention/decision.
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Another option for interpreting EIS spectra is based on the
analysis of Poisson-Nernst-Planck equations (PNP).[67–69] The
simplest case of PNP assumes the presence of only positive and
negative ions in the solution. For simplicity, only a one-
dimensional case is described. The sample solution is placed
between the electrodes sited at positions 0 and d. A simplified
geometry of the system is shown in Figure 3. The recombina-
tion and further reaction of ions in solution for simplicity is
excluded. The external perturbation of an electrical field is
small, so only local oscillation in the concentration is assumed
[Eq. (5)].[70]
ci ¼ c0 þ ci1 exp iwtð Þ; i ¼ cation=anion ð5Þ
where ci is the bulk concentration and ci1 is the local
concentration of ion. The c0 is thermodynamically bulk ion
concentration. The electrodes are perpendicular to the z axis.
Once these assumptions are taken into account, the governing
equations for the electric field are described in the Poisson
equation [Eq. (6)],[71]
@2V
@z2
¼  q
e
c11  c21ð Þ ð6Þ
and the conservation law for the ions [Eq. (7)] as:
@ci1
@t
¼ D @
@z
@ci1
@z
 q
KBT
ðc0 þ ci1Þ @V
@z
 
ð7Þ
where e is the permittivity of the liquid, q is the elementary
charge, KB is the Boltzman constant, D is the diffusion
coefficient (assuming that the cations and anions have an equal
value of D), z is the spatial coordination. Note that all
concentrations are spatial and time-resolved: c0=c0(z,t), ci1=ci1
(z,t), V=V(z,t). The boundary condition for the electric field
[Eq. (8)] is:
V z0; tð Þ ¼ Vmax
2
exp iwtð Þ ð8Þ
The boundary conditions for the ions are[72]:
A) Blocking boundary conditions. The ion current for cations
and anions is 0 [Eq. (9)]:
@ci1 z0; tð Þ
@z
 q
KBT
c0 z0; tð Þ þ ci1 z0; tð Þð Þ @V z0; tð Þ
@z
¼ 0; z0 ¼ 0; d
ð9Þ
B) Chang-Jaffe boundary conditions. The ion current is propor-
tional to the concentration of ions [Eq. (10)]:
@ci1 z0; tð Þ
@z
 q
KBT
c0 z0; tð Þ þ ci1 z0; tð Þð Þ @V z0; tð Þ
@z
¼ kci1 z0tð Þ z0 ¼ 0; d
ð10Þ
C) Ohmic boundary. The ion current is proportional to the
surface electric field [Eq. (11)]:
@ci1 z0; tð Þ
@z
 q
KBT
c0 z0; tð Þ þ ci1 z0; tð Þð Þ @V z0; tð Þ
@z
¼ sV z0tð Þ z0 ¼ 0; d
ð11Þ
After the Laplace transformation, the partial differential
equations are reduced to ordinary differential equations. Some
useful substitutions are necessary to solve these equations.[73]
These substitutions can be summarized as follows [Eq. (12)]:
(12)
where Z is the dimensionless coordinate, d is the length
between the electrodes, t is the dimensionless time, capital C is
the dimensionless concentration and ld is the Debye length.
The governing equation can then be expressed as [Eq. (13),
(14)]:
L2
@2f
@Z2
¼ c0 C11  C21ð Þ ð13Þ
@ci1
@t
¼ Lc0 @
@Z
@ci1
@Z
þ 1þ Ci1ð Þ @f
@Z
 
ð14Þ
The NP equation is Laplace transformed to [Eq. (15)]:
iwCi1 ¼ Lc0 @
@Z
@ci1
@Z
þ 1þ Ci1ð Þ @f
@Z
 
ð15Þ
Note that now all C, f are frequency- and spatial-
coordinate- dependent.
The numerical result of this equation is shown in Figure 3.
The blocking boundary conditions have a Nyquist plot similar
to the equivalent circuit shown in Figure 2. The Ohmic
boundary has a Nyquist plot similar to a circuit with 2
resistances.
Following the assumption that the bulk concentration c0 is
much larger than ci1, c0@ci1 this model has an analytical
solution and can serve as a benchmark for the numerical
computations.[72] The application of PNP with slight modifica-
tions is used for Li-batteries simulation,[74,75] transport,[76] bio-
sensors,[77] etc.
One of the modifications of the PNP system was used to
simulate ionic polymer composites (IPMC). This two-layer
system consists of IPMC and a polymer membrane. In the
Figure 3. Nyquist plot for different boundary conditions (solid: blocking;
dashed: Chang-Jaffe; dash-dotted: Ohmic boundaries).
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composite layer, free electrons can migrate and the total
current generated is the sum of the migrating ions and
electrons. This system can be simulated with an equivalent
circuit, consisting of resistance, capacitance and Warburg
impedance element in parallel.[78] A further implementation of
the PNP system was to model a zwitterionic hydrogel layer. The
zwitterionic hydrogel layer contains four different ions i. e., H+
and OH ions from the hydrogel and cations and anions from
the electrolyte solution. Moreover, an equilibrium pertains
between the H+ and OH ions governed by the dissociation
constant at a particular pH of the electrolyte. The result from
the simulations was that the hydrogel resistance and double-
layer capacitance depend on the pH value.[70]The simulations in
the area of biosensors are based on the assumption that a large
biomolecule has a dielectric constant very different from that of
the electrolyte.[79] Hence, in this case, the biomolecule has a
different capacitance and resistance. In the dimensional case,
the biomolecule is simulated as a layer with parameters
different from the bulk electrolyte. This basic one-dimensional
model with Nyquist plots for various L2 positions is shown in
Figure 4.[80] The models were applied to simulations on the
nanoelectrodes set in the array format. There are attempts to
model the interfacial biosensor’s interfaces in two/three spatial
dimensions. The impedimetric biosensor with a passivation
layer was subsequently used for detecting pathogen bacterial
cells.[81]
4. EIS as a Powerful Tool for Sensitive
Detection of Cancer Biomarkers
The phrase “tumor marker” is often transposed for the term
“biomarker” and vice versa. According to the National Institutes
of Health, a biomarker is defined as a cellular, biochemical and/
or molecular characteristic that can be objectively measured
and evaluated as an indicator of normal biological processes,
pathological processes or pharmacological responses to ther-
apeutic intervention.[82] In contrast, the definition of a tumor
marker is more specific. A tumor or cancer marker may be
defined as a substance produced by a tumor or by the host in
response to a cancer cell that can be objectively measured and
evaluated as an indicator of cancerous processes within the
body.[83] To date, the U.S. Food and Drug Administration (FDA)
has approved 19 protein cancer markers, 11 present in blood, 5
detectable in tissue and 3 located in urine (Table 1).[84] Although
various methods were tested for the evaluation of these
markers, there are just a few markers which were detected by
the EIS-based biosensors.
4.1. a-Fetoprotein
a-Fetoprotein (AFP) is a serum protein with a molecular mass of
70 kDa, which is produced by the yolk sac and the liver during
fetal life. Normally, the level of AFP in the serum of healthy
human individuals is under 25 ngmL1, but this value rises with
the development of some cancerous diseases (hepatocellular
cancer, yolk sac cancer, liver metastasis from gastric cancer,
testicular cancer, and nasopharyngeal cancer). Accordingly, it is
one of the most extensively used clinical cancer biomarkers.[85]
In 2013, Zhang and co-workers developed a sensitive label-
free electrochemical EIS biosensor array based on five screen-
printed carbon electrodes (SPCE) covered with carboxyl-
functionalized single-wall carbon nanotubes (SWNTs) for the
detection of AFP.[86] Molecules of wheat-germ agglutinin (WGA)
lectin were immobilized on the SWNTs layer and served as a
Figure 4. Nyquist plot for different position of layer. Solid line is the nearest
to the electrode, dash-dotted is the furthest.
Table 1. List of FDA-approved protein cancer biomarkers.[84]
Biomarker Sample Use Cancer Assay
AFP S St TeCa IA
b-hGC S St TeCa IA
CA 19–9 S Mo PaCa IA
CA 125 S Mo OvCa IA
CA 15.3 S Mo BCa IA
CA 27.29 S Mo BCa IA
CEA S Mo CCa IA
FDP S Mo BlCa IA
HE4 S Mo OvCa IA
PSA S Sc& Mo PCa IA
TG S Mo TCa IA
EGFR T Pre CCa IHC
KIT T Pre GaCa IHC
ER T Pre & Pro BCa IHC
PR T Pre & Pro BCa IHC
HER2-neu T Pre & Pro BCa IHC
NMP/22 U Sc& Mo BlCa IA
BTA U Mo BlCa IA
› Mw CEA U Mo BlCa IF
Abbreviations: AFP: a-fetoprotein; b-hGC: human chorionic gonadotropin-
b; CA 19–9: carbohydrate antigen 19–9; CA 125: carbohydrate antigen 125;
CA 15.3: carbohydrate antigen 15.3; CA 27.29: carbohydrate antigen 27.29;
CEA: carcinoembryonic antigen; FDP: fibrin/fibrinogen degradation pro-
ducts; HE4: human epididymis protein 4; PSA: prostate specific antigen; TG:
thyroglobulin; EGFR: pidermal growth factor receptor; KIT: v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog; ER: estrogen
receptor; PR: progesterone receptor; HER2-neu: human epidermal growth
factor receptor 2; NMP/22: nuclear matrix protein 22; BTA: bladder tumour
antigen; › Mw CEA: high molecular mass CEA; S: serum; U: urine; T: tissue;
St: staging; Mo: monitoring; Sc: screening; Pre: predictions; Pro: prognosis;
TeCa: testicular cancer; PaCa: pancreatic cancer; OvCa: ovarian cancer; BCa:
breast cancer; CCa: colorectal cancer; BlCa: bladder cancer; PCa: prostate
cancer; TCa: thyroid cancer; GaCa: gastrointestinal cancer; IA: immunoas-
says; IHC: immunohistochemistry; IF: immunofluorescence.
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specific recognition element. The biosensor had a linear
response range from 1 to 100 ngL1 with LOD of 0.1 ngL1. In
addition, thanks to a lectin-based biosensor array prepared
with five different lectins, it was possible to discriminate
between healthy and cancer patients serum samples based on
different glycan compositions in AFP protein.[86]
Yuan with his team just a year later showed the integration
of nanomaterials into an EIS assay format for the detection of
AFP.[87] They prepared a sandwich-type EIS immunosensor
(Figure 5). The biosensor was built on a glassy carbon electrode
(GCE) modified with gold nanoparticles/graphene nanosheet
nanocomposites (Au-Gra), which served as a matrix for the
attachment of primary antibodies (Anti1-AFP). The second step
was the application of a complex consisting of secondary
antibodies (Anti2-AFP) and two enzymes (horseradish
peroxidase-HRP and glucose oxidase-GOx) attached to the
surface of functionalized single-walled carbon nanohorns
(SWCNHs). The biocatalyst accelerated the oxidation of 4-
chloro-1-naphthol (4-CN) by H2O2 to yield an insoluble product
on the electrode, which blocked the interfacial electron transfer
of a redox probe and thus enhanced detection sensitivity. The
immunosensor showed a wide dynamic range between
1 pgmL1 and 60 ngmL1 with LOD of 0.33 pgmL1.[87]
A novel gold nanoparticles-poly(propylene imine) den-
drimer- based platform was developed for the impedimetric
detection of AFP.[88] The immunosensor thus prepared was used
to detect AFP over a wide concentration range from 0.005 to
500 ngmL1 with LOD of 0.00185 ngmL1.[88]
4.2. Carcinoembryonic Antigen
Carcinoembryonic antigen (CEA) is a highly glycosylated cell
surface protein consisting of approx. 60% carbohydrates; its
molecular mass is around 180–200 kDa.[89] The level of CEA in
the serum of adult non-smokers is below 2.5 ngmL1 and in the
serum of smokers below 5.0 ngmL1 and an elevated level of
CEA is associated with lung cancer, breast cancer, colon cancer
and cystadenocarcinoma.[90] Hence, the rapid and sensitive
detection of low concentrations of CEA in serum could be the
key to the early diagnosis of cancer and the further monitoring
of the response of tumors to therapy. A large number of papers
have been published detecting CEA in recent years, but only a
few were based on EIS detection.
Fan with co-workers and Wang with his team prepared
biosensors with linear ranges at the ngmL1 concentration
level, both using GCE modified with gold nanoparticles (AuNPs)
with immobilized anti-CEA antibodies as a biorecognition
element.[91,92] Another team sought to construct EIS biosensors
employing staphylococcal protein A for the controlled immobi-
lization of IgG with binding Fab fragments exposed to the
electrolyte for binding their target antigens.[93] Staphylococcal
protein A was immobilized onto AuNPs, which covered the
surface of the gold electrode. Characterization of the biosensor
revealed that EIS as well as cyclic voltammetry (CV) techniques
can be employed for the determination of CEA, with EIS being
the more sensitive. The biosensor exhibited LOD of 0.1 pgmL1
with a good linear response to CEA in a range from 1 pgmL1
to 100 ngmL1.[93]
The team of Professor Liu combined two methods: EIS and
UV-Vis spectroscopy for sensitive CEA detection.[94] Their
optoelectronic immunosensor was based on a gold-modified
indium tin oxide (ITO) electrode and thiol-derivative-nanogold-
(TDN)-labelled anti-CEA antibody. The linear range was ob-
served between 0.05 and 80 ngmL1 for EIS and 0.5 and
80 ngmL1 for the UV method, respectively. EIS also exhibited a
LOD (1 pgmL1) lower than the UV method (2 pgmL1).[94]
A higher sensitivity of the EIS immunosensor was achieved
by using a combination of AuNPs with biocompatible polymeric
nanoparticles g-PGA-DA@CS, which were created by the self-
assembling of chitosan (CS) and dopamine-modified poly(g-
glutamic acid) (g-PGA-DA).[95] GCE was covered with g-PGA-
DA@CS in a process of electrophoretic deposition. Subse-
quently, AuNPs were anchored onto g-PGA-DA@CS film and
served as a highly stable and biocompatible immobilization
platform for the attachment of monoclonal anti-CEA antibodies.
The EIS response of the immunosensor changed linearly from
20 fgmL1 to 20 ngmL1 with very low LOD of 10 fgmL1.[95]
Because CEA is a cell surface protein, it is desirable to detect
CEA-positive cells. There are two very important factors to be
taken into account in the fabrication of an electrochemical
cytosensor: electron transfer efficiency and biocompatibility. Jia
with co-workers addressed these issues by using Au@BSA
microspheres.[96] Au improved the electron transfer towards the
electrode and bovine serum albumin (BSA) played a key role in
achieving the biocompatibility. The Au@BSA microspheres thus
prepared were applied on a gold electrode and were
subsequently conjugated with anti-CEA antibodies via gluta-
raldehyde. Under optimal conditions, the final cytosensor
exhibited a wide linear range from 5.2101 to 5.2
107 cellsmL1 with LOD of 18 cellsmL1.[96]
An alternative to antibodies as biorecognition elements are
aptamers. The selective and sensitive detection of CEA was
Figure 5. Preparation of SWCNHs-bienzymatic-Anti2-AFP bioconjugates us-
ing carboxy-groups on surface (A) and stepwise functionality of a modified
electrode (B), where GCE is modified by Au-Gra layer and subsequently with
anti-AFP antibody. AFP is detected in a sandwich configuration. Reprinted
from [87], Copyright 2014 with permission from Elsevier.
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achieved applying a platform based on (anti-CEA)/PBSE/
Graphene/Cu-modified GCE by Srivastava and co-workers. The
biosensor so developed exhibited a linear response in the
physiological range of 1.0–25.0 ngmL1 (normal value:
~5.0 ngmL1), revealing a sensitivity of 563Wng1mLcm2
with a correlation coefficient of 0.996 and LOD of
0.23 ngmL1.[97] In 2017, a specific aptasensor for the determi-
nation of CEA was constructed by Xu’s team.[97] Their sensitive
impedimetric aptasensor was based on a catalytic cascade for
signal-amplification (Figure 6).
The biosensing principle was based on the use of Cu-based
metal organic frameworks (MOFs) coated with Pt nanoparticles
(PtNPs) to obtain Pt@CuMOFs. After covering these particles
with G-rich aptamer and hemin, the conformation of the CEA
aptamer switched to hemin/G-quadruplex (hGq) (combination
of iron-containing porphyrin and G-rich single-stranded DNA –
mimicking a peroxidase-like activity). After adding glucose
oxidase (GOx), they obtained Pt@CuMOFs-hGq-GOx, which
acted as a signal transduction probe (STP). To detect CEA in
samples, the CEA aptamer was immobilized on GCE with an
electrodeposited Au layer. After incubation with CEA, a
sandwich was formed by incubation with the STP and after the
addition of glucose and dye, an insoluble precipitate was
formed, which increased the impedimetric signal. The biosensor
was able to detect CEA sensitively within a linear range from
0.05 pgmL1 to 20 ngmL1 with LOD of 0.023 pgmL1.[98]
Biomimetic materials are a relatively new type of biorecog-
nition element in the construction of biosensors. Sales with co-
workers constructed a CEA impedimetric sensor based on a
“plastic antibody” assembled on an Ag-working electrode.[99]
The advantage of this sensor was the low cost of the screen-
printed Ag working electrodes prepared via printed-circuit
board technology. The biomimetic material was prepared by
the electropolymerization of pyrrole in the presence of CEA.
After the formation of a polypyrrole matrix, CEA molecules
were removed from the matrix by a proteolytic enzyme
proteinase K creating a vacant site for the binding of CEA from
the samples analyzed. The device exhibited a linear response
from 0.05 to 1.25 pgmL1 of CEA.[99] Finally, dye sensitized solar
cells were fabricated with a counter electrode made of
polypyrrole (PPy) that was made responsive to a specific
protein by biomimetic material (BM) technology.[100] The
resulting BM-PPy film acted as a biomimetic artificial antibody
for CEA with LOD of 0.13 pg mL1 [100]
4.3. Human Epidermal Growth Factor Receptors
The family of human epidermal growth factor receptors (HER/
ErbB) includes four homologues: EGFR (HER1 or ErbB-1), HER2
(ErbB2), HER3 (ErbB3) and HER4 (ErbB4). These glycoproteins
have a molecular mass ranging from 170 to 185 kDa and are
localized in the cell membrane; they consist of an extracellular
ligand-binding domain, a transmembrane part and an intra-
cellular domain which possesses a tyrosine kinase activity.[101,102]
The chrono-impedance technique was applied to real-time
monitoring of the interaction between HER3 and anti-HER3 as a
biorecognition element.[102] The impedimetric biosensor based
on self-assembled monolayers (SAMs) of 4-aminothiophenol on
gold electrodes exhibited a linear response range from 0.4 to
2.4 pgmL1 with LOD of 0.28 pgmL1 (Figure 7).[102] The extrac-
ellular domain of these proteins serves as a binding site for
ligands such as epidermal or transforming growth factors. After
the attachment of a relevant ligand, tyrosine kinase activity in
the intracellular domain is promoted, causing cell differentia-
tion and proliferation.[103] Even though there is no known ligand
which binds to HER2, the protein can be activated by the
formation of heterodimers with other members of HER family
receptors. For example, the HER2/HER3 dimer is the most
potent oncogenic pair. During the formation of this dimer,
kinase activity is switched on followed by the activation of
downstream signaling pathways. The over-expression of mem-
Figure 6. A) Preparation process of Pt@CuMOFs-hGq-GOx complex, B)
Preparation of impedimetric aptasensor using Au-modified GCE electrode,
aptamers, BSA as a blocking agent, and CEA as an analyte. Again, a sandwich
configuration using the complex was used for CEA detection and glucose
was used for hydrogen peroxide production using GOx and thus signal
generation after a cascade reaction. C) Cascade catalysis amplification to
form non-conductive insoluble precipitates (IPs), resulting in an increase in
RCT value. Reprinted from,
[98] Copyright 2017, with permission from Elsevier.
Figure 7. Schematic representation of immobilisation steps of anti-HER3
onto Au electrode. Reprinted from,[102] Copyright 2014, with permission from
Elsevier.
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bers of HER/ErbB family is hence associated with various types
of cancer.[104,105] EGFR (HER1/ErbB1) was the first known growth
factor receptor from HER family related to oncoproteins.[106] Its
over-expression is associated with various tumors (non-small
cell lung cancer, breast, ovarian, prostate, pancreatic, renal,
head and neck, colorectal cancer, etc.) and also with a poor
prognosis and development of aggressive disease stages.[107]
Zoroub with co-workers manufactured an EIS immunosen-
sor for the sensitive determination of EGFR in samples.[108] The
core of the biosensor consists of a polycrystalline Au electrode
covered with AuNPs, an amine-terminated self-assembled
monolayer (formed from cysteamine), a 1,4-phenylene diiso-
thiocyanate linker and protein G applied to the controlled
immobilization of antibodies. The biosensor exhibited a linear
response from 1 pgmL1 to 1 mgmL1 with LOD of
0.34 pgmL1.[108] HER2 (ErbB2) is one of the best characterized
and most widely used biomarkers. Physiological levels of HER2
in the blood of healthy people range from 4 to 14 ngmL1,
while its concentration in the blood of cancer patients is higher
(14–75 ngmL1). HER2 is over-expressed in around 20–30% of
breast cancer patients and is also associated with an aggressive
form of the disease and a poor prognosis.[109,110] Higher levels of
HER2 were also observed during gastric, oesophageal, ovarian
and endometrial cancers. Currently, there are two standardized
methods for HER2 analysis (immunochemistry and in-situ
fluorescence hybridization), but approximately 20% of assays
are not accurate.[111]
Professor Lee with his team used a single-stranded DNA
aptamer for the development of a biosensor.[112] Gold electrodes
were covered with AuNPs and subsequently modified by 3-
mercaptopropionic acid to produce SAM. A specific DNA
aptamer was terminated with the amine group to form a
covalent linkage with 3-mercaptopropionic acid. The biosensor
exhibited good selectivity and sensitivity, and was able to
detect the HER2 analyte in a linear fashion from 105 to
102 ngmL1. A great advantage of this aptasensor was its simple
regeneration by a pH-shift method, whereby a regenerated
sensor worked as efficiently as a freshly prepared one.[112]
Marrazza’s group used an affibody as a biorecognition
element for the design of a label-free HER2 biosensor.[113]
Affibodies are affinity proteins with low molecular mass
(6.5 kDa), produced by protein engineering of one of the five
stable a-helix bundle domains from IgG Fc-binding fragment of
protein A from Staphylococcus sp.[114,115] Marrazza’s affibodies
were terminated with cysteine for better immobilization on the
biosensor interface, which was formed by the deposition of
nanostructured gold on graphite SPE modified with AuNPs and
covered with 6-mercapto-1-hexanol to form SAM. Under
optimal conditions, the affisensor could detect the human
epidermal growth factor receptor 2 with LOD of 6.0 mgmL1
within a linear range from 0 to 40 mgmL1.[113]
A thiol-terminated DNA aptamer with an affinity towards
HER2 was used to prepare the bio-recognition layer via self-
assembly on interdigitated gold surfaces.[109] Non-Faradai-
c EIS measurements were used as a detection scheme by
detecting changes in capacitance. The aptasensor exhibited a
linear range for the determination of HER2 from 1 pM to
100 nM in both a buffer and in undiluted serum with LOD
below 1 pM.[109]
HER3 (ErbB3) was identified thanks to its homology to
EGFR, but it was noted that the protein is the only member of
the HER family which has impaired kinase activity. Normal levels
of HER3 in a healthy person lie within 0.06 to 2.55 ngmL1 and
its over-expression (level increased up to 12 ngmL1) is
associated with carcinomas of the breast, lung, oral cavity,
ovarian, prostate, colon, pancreas and stomach.[116]
A novel Affimer-functionalized interdigitated electrode-
based capacitive biosensor platform was developed for the
detection and estimation of Her4 in undiluted serum.[117] The
Affimer sensor exhibits high assay sensitivity with a wide
dynamic range (from 1 pM to 100 nM) and LOD lower than
1 pM in both a buffer and in serum.[117]
We showed very recently, that also glycoprofiling of HER2
receptor in human sera might be a promising disease
biomarker in the future (even though HER2 negative breast
cancer patients without any serological HER2 are fairly
common).[118] A disposable biosensor based on screen printed
carbon electrodes with a deposited photoimmobilizable zwit-
terionic hydrogel layer was applied for covalent attachment of
antibodies for a specific interaction with HER2 and subse-
quently for successful in-situ glycoprofiling of HER2 molecules
using lectins. The EIS immunosensor detected HER2 down to
5 pgmL1 (77 fM) with a minimal non-specific protein
adsorption.[118]
A novel and potentially promising area emerged recently –
assay of exosomes and microvesicules.[119] Nanoscale extracel-
lular vesicles (EVs) including exosomes (membrane particles
with size 50–150 nm) appeared as promising cancer biomarkers
since they carry genetic information about the parental cells.
Label-free EIS sensor measuring EVs secretion levels from
hypoxic and normoxic MCF-7 cells (a breast cancer cell line)
exhibited linear range from 102 to 109 EVsmL1 with LOD of
77 EVsmL1.[119]
4.4. Carbohydrate Antigen 125, Carbohydrate Antigen 15.3,
and Human Epididymis Protein 4
Carbohydrate antigen 125 (CA-125), also known as mucin 16
(MUC16), is a member of the mucin glycoproteins which
contains 22,000 amino acids. It is significantly expressed by
most ovarian epithelial tumors, but also by the normal
epithelium of the female reproductive system, gastrointestinal
mucosal cells, and by the luminal surface of the mesothelium
lining the peritoneum, pleura and pericardium.[120]
The micro-flow label-free impedimetric biosensor was
developed for the detection of CA125.[121] The immunosensor
was based on the use of thin-film interdigitated gold-array
microelectrodes (IDA). A good analytical performance for
CA125 detection (from 0 to 100 U mL1) was achieved through
the electropolymerization of anthranilic acid on IDA electrodes
followed by the covalent attachment of the anti-CA125
monoclonal antibody. The estimated LOD (3Sblank/Slope) for
CA125 was 7 UmL1.[121]
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Carbohydrate antigen 15.3 (CA 15.3) was detected applying
the immunoelectrode (anti-CA 15.3/SnO2/Pt/Ti/glass).
[122] The
impedimetric biosensor (anti-CA 15.3/SnO2/Pt/Ti/glass) exhib-
ited a linear increase in the response upon incubation with CA
15–3, across a wide range of antigen concentrations from
50 ngdL1 to 700 ngdL1 (8 UmL1 to 120 UmL1) with bio-
sensor sensitivity of 38.6 W (ngdL1)1, fast response time and a
long shelf-life of more than 20 weeks.[122]
The human epididymis protein 4 (HE4) is a biomarker
approved by the FDA for monitoring patients with epithelial
ovarian cancer. The typical molecular mass of the protein is
~13 kDa for a single 50 amino acid non-glycosylated peptide
HE4 molecule, classified as a whey acidic four-disulphide core
protein.
HE4 is encoded by the WFDC2 gene located on chromo-
some 20q12-13.1 and belongs to the family of whey-acidic four-
disulphide core proteins with suspected trypsin-inhibitor prop-
erties. HE4 is upregulated in ovarian cancer compared to other
types of carcinomas and benign ovarian tumors.[123,124] The
interdigitated electrode arrays with nano-scale gaps have been
also successfully applied as a platform to the label-free
detection of HE4.[124] The biomarker of ovarian cancer HE4 was
detected along with CA-125 and CEA, which are well-
established ovarian cancer biomarkers (Figure 8). The label-free
impedimetric sensor successfully detected HE4 down to
1.5 ngmL1 and this electronic sensor was able to differentiate
all three biomarkers present in the same sample down to
100 pgmL1.[124]
4.5. Prostate Specific Antigen and p53 Protein
Prostate cancer (PCa, adenocarcinoma or glandular cancer of
the prostate gland) represents the second commonest cancer
in men worldwide, with an estimated 1.1 million cases
diagnosed in 2012 alone. The prostate-specific antigen (PSA)
belongs to the tissue kallikrein-related family of peptidases and
is also known as g-seminoprotein, kallikrein-3 or KLK3. PSA is a
28.4 kDa glycoprotein containing approximately 8% (by mass)
of N-glycan with a single glycosylation site.
EIS was successfully applied as a label-free and non-
destructive method to detection of the PSA cancer biomarker
with low LODs.[125,126] The impedimetric biosensor based on
recombinant single-chain antibody fragments (scAb), fragments
covalently immobilized on the gold electrode surface, pat-
terned by a mixed SAM using standard amine-coupling
chemistry was developed.[125] The non-specific protein-binding
was investigated applying a kallikrein 2 protein (a protein
structurally similar to PSA) and the results indicated a high
selectivity for PSA detection.[125] The impedimetric biosensor
device was able to detect PSA down to 100 agmL1 with a
linear concentration working range from 100 agmL1 up to
1 mgmL1 (Figure 9).[127]
PSA analysis using a label-free PSA aptasensor and PSA
immunosensor was based on graphene quantum dots-gold
nanorods (GQDs-AuNRs) modified screen-printed electrodes.[128]
Two modes of operation i. e., voltammetric and EIS techniques
exhibited significant potential for reliable detection of the
disease. Both sensors detected PSA with an almost same LOD
of 0.14 ngmL1.[128]
Besides the detection of PSA, the EIS-based biosensor also
made it possible to glycoprofile PSA using lectins on the same
interface.[36] PSA could be detected down to 4 aM and the same
ultralow PSA concentration could be applied to PSA glycoprofil-
ing.[36]
A label-free immunosensor based on a tetra-armed star-
shaped poly(glycidylmethacrylate)-modified disposable ITO
electrode was fabricated for the detection of p53 protein, an
important colorectal cancer biomarker.[129] The disposable im-
Figure 8. a) The nanogap IDEA chip with an array of eight IDEAs designed
with contact electrodes in a SD card format. b) Photomicrograph of an
individual IDE with 39 digits from each end. c) and d) SEM and AFM profiles
of the IDEAs, e) shows the immobilisation process for multiplexed biosensor
using physical segregation of electrodes using a PDMS mask. The chip was
an integral part of the measurement set-up and microfluidics within a PDMS
channel (f). Reprinted by permission from Springer,[124] COPYRIGHT (2012).
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munosensor exhibited LOD of 7 fgmL1 and a linear detection
range between 0.02 pgmL1 and 4 pgmL1.[129]
A label-free immunosensor based on a tetra-armed star-
shaped poly(glycidylmethacrylate)-modified disposable ITO
electrode was fabricated for the detection of p53 protein, an
important colorectal cancer biomarker.[129] The disposable im-
munosensor exhibited LOD of 7 fgmL1 and a linear detection
range between 0.02 pgmL1 and 4 pgmL1.[129]
5. Challenges and Obstacles to
Commercialization
For any potential application in clinical practice, the device
needs to be able to perform robustly in a real sample without
any further steps being required to provide a rapid method,
and with a minute sample consumption. To enhance the
performance of affinity biosensors, nanostructured interfaces
are often prepared to increase the amount of probe immobi-
lized on the surface.[130,131]
Increased interfacial density of the ligand can extend the
linear range of the biosensor; however, if the probe density is
too high, the biorecognition event can be suppressed due to
steric hindrance.[45,135] This phenomenon varies from case to
case, depending on the size and shape of the probe and the
analyte, hence each device needs to be optimized and
calibrated individually. For calibration of the device, positive
and negative controls are often needed on the same surface,
thus an array format of analysis is required,[136] reducing the
input costs, increasing assay throughput and assay reliability.
Mass production would also lead to the surfaces being
produced in a reproducible way, as referred to in papers
published to date. Sensitivity of detection is another very
important issue since the biosensors need to detect low
abundant cancer biomarkers with levels down to sub-ng mL1
(Table 2).
Some of the highly abundant proteins in human serum may
significantly interfere with analyte detection, lowering assay
selectivity. It is, however, possible to reduce non-specific
adsorption to a minimal level using surface modifications by
different functionalities. For this purpose, molecules able to
strongly bind and orient water molecules are applied to create
a barrier against any non-specific interactions. Such surfaces
highly resistant towards non-specific protein/cell binding are of
interest not only for biomedical purposes (catheters and
medical implants) but also to the food industry and to marine
coatings.[137–143] Different molecules have been used to date,
(especially in the form of hydrogels or SAMs),[139–141] mostly
based on oligo(ethyleneglycol) (OEG) moieties or betaine
derivatives.[41,142,144] In particular, zwitterionic betaine-based
molecules are used to prepare 3D hydrogel layers, which are
most effective in resisting non-specific protein-binding.[145]
Finally, for more user-friendly applications, analysis of other
body fluids (not just serum samples) might be of a great
importance in the field of impedimetric biosensing. For
Figure 9. Construction of the biosensor device showing sensing of PSA and
glycoprofiling of PSA by application of lectin. Reprinted from,[127] Copyright
2016, with permission from Elsevier.
Table 2. Brief overview of some recently published impedimetric biosensors for relevant cancer biomarkers detection.
BM Cancer Sensor LR LOD Reg. Ref
AFP HpCa GCE/CNH 0.001–60 ngmL1 0.33 pgmL1 –
[87]
CA125 OvCa Au/#1 0–0.1 UmL1 0.0016 UmL1 A
[132]
CEA CCa, PaCa, GaCa, BCa GCE//#2 20 fg–20 ngmL1 10 fgmL1
[95]
HER2 BCa GSPE/AuNP 0–40 mgL1 6.0 mgL1 B
[113]
HER2 BCa Au/AuNP 105–102 ngmL1 5 ngmL1 C
[112]
HER2, HER4 BCa IDmEs 1pM–100 nM 1 pmolL1
[109]
HE4 OvCa IDEA 1.5–25 ng mL1 1.5 ngmL1 –
[121]
FR_HeLa CCT BDD/AuNP 10–105 cellsmL1 10 cellsmL1 D
[133]
PSA PCa Au 100 ag-1 mgmL1 100 agmL1 -
[127]
RACK1 * ITO 14–713 fgmL1 30 fgmL1 E
[134]
Abbreviations: BM: biomarkers; AFP: a-fetoprotein; GCE: glassy carbon electrode; SNH: single-walled carbon nanohorns; CA125: carbohydrate antigen 125; Au:
gold electrode; #1: silica-coated gold nanoparticles; CEA: carcinoembryonic antigen; #2: gold nanoparticles and polymeric self-assembled nanoparticles (g-
PGA-DA@CS: chitosan and dopamine modified poly(g-glutamic acid); HER2: human epidermal growth factor receptor 2; AuNP: gold nanoparticles; GSPE: gold
nanostructured screen-printed graphite; IDmEs: interdigitated gold micro-electrode arrays on silicon/silicon oxide wafers“; HE4: human epididymis protein 4;
IDEA: nanogap interdigitated electrode array (gold electrodes); FR_HeLa: folate receptor-rich human cervical carcinoma cells; BDD: boron-doped diamond
electrode; PSA: prostate-specific antigen; RACK1: Receptor for Activated C Kinase 1; HpCa: hepatocellular cancer; GaCa: gastric cancer; CCT: cancerous cervical
tumour; PCa: prostate cancer; ITO: indium tin oxide electrode; LR: linear range; * different types of cancer: oral squamous cell carcinoma, melanoma, colon
cancer, on-small cell lung cancer, hepatocellular carcinoma and breast cancer; Reg: regeneration conditions; A: 0.15 M glycine-HCl, pH 2.0); B: 2 M HCl; C: PBS
pH 4.0; D: 0.1 M citric acid/glycine/HCl, pH 3.0; E: 0.1% HCl.
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example analysis of interleukin 1b in a human saliva was
performed.[146] An impedimetric immunosensor detected the
analyte using a semi-conductive poly(2-thiophen-3-yl-malonic
acid) (P3-TMA) layer as an immobilization matrix material and
anti-IL-1b antibody as a biorecognition element. The relative
change in impedance was proportional to the IL-1b concen-
tration in the range from 0.01 to 3 pgmL1 with LOD
3 fgmL1.[146]
6. Conclusions
This review details the theory of interfacial processes on the
electrode surface and in close proximity to the conductive
interface, which can significantly influence the electrochemical
behaviour of the system. As a result, deviation from simple
Nyquist plots could be observed, which can further complicate
the evaluation of EIS assays. The article also describes what is
required of EIS-based assays for successful integration into a
device which could be applied in clinical practice or to design
domestic devices. Finally, EIS-based assays protocols for the
detection of cancer-associated biomarkers are described with
details provided of the basic performance characteristics of
these affinity-based biosensor devices. The article also discusses
the need to address the non-specific binding of components
from complex samples to design selective EIS-based biosensors.
So far especially antibody-based EIS biosensors have been
constructed. It can be envisioned that biorecognition elements
smaller than antibodies such as antibody fragments, DNA/RNA
aptamers and peptide aptamers might in the future improve
operational characteristics of affinity impedimetric biosensors
such as enhanced operational/storage stability, sensitivity,
specificity, assay reproducibility, robustness of a bioconjugation
process and resistance towards non-specific binding from
complex samples.
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